Survival analysis on HIV/AIDS cases who newly received antiretroviral therapy and coinfected with hepatitis B virus in Jiangsu Province,2005-2020  

作　　者：邱涛 QIU Tao(Dept HIV/STD Prev&Contr,Jiangsu Prov Dis Contr&Prev Center,Nanjing 210009)

机构地区：[1]Dept HIV/STD Prev&Contr,Jiangsu Prov Dis Contr&Prev Center,Nanjing 210009

出　　处：《China Medical Abstracts(Internal Medicine)》2024年第2期85-86,共2页中国医学文摘（内科学分册（英文版）

摘　　要：Objective To analyze the incidence of co-infection of HIV and HBV and death in HIV/AIDS cases who newly received antiretroviral therapy(ART)from 2005-2020 in Jiangsu Province.Methods According to the baseline and follow-up data of HIV/AIDS cases on ART enrolled between January 2005 and December 2020,the last follow-up clinical visit was until December 31,2022,and the national information system was retrospectively collected for HIV/AIDS cases from Chinese System Disease for Control and Prevention.Excel database was established,and statistical analysis was performed using the SPSS 16.0 software.Kaplan-Meier method was used to draw the survival curves,the log rank test was used to compare the survival curves,and Cox proportional hazards modeling was used to assess the mortality and potential risk factors.Results There were 33322 HIV/AIDS cases that newly received ART during 2005-2020.The rate of HBsAg test was 57.3%(19098/33322).Among HIV/AIDS cases tested HBsAg,the ratio of male to female was 7.1:1(16745:2353)with an average age of(39.4±14.0)years old,49.5%(9446/19098)of the HIV/AIDS cases were married.

关 键 词：CASES HIV/AIDS SURVIVAL 

分 类 号：R512.91[医药卫生—内科学] R512.62[医药卫生—临床医学]